Nanovector therapeutics

被引:90
作者
Ferrari, M
机构
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] NCI, Bethesda, MD 20892 USA
关键词
D O I
10.1016/j.cbpa.2005.06.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
An ideal injected therapeutic drug would travel through the vasculature, reach the intended target at full concentration, and there act selectively on diseased cells and tissues only, without creating undesired side effects. Unfortunately, even the best current therapies fail to attain this ideal behavior, by a wide margin. A primary reason is the fact that the target recognition abilities of the current therapeutics molecules are quite limited. Furthermore, the natural defenses of the body present a sequence of formidable obstacles on the drug's pathway to the intended lesion. Requiring any molecule to have sufficient therapeutic efficacy, target recognition specificity, as well as all of the tools required to bypass multiple biological barriers is probably unrealistic. A different approach is to decouple the problem (i.e. employ the drug molecules for their therapeutic action only, and deliver them to the intended site by vectors that can be preferentially concentrated at desired body locations through the concurrent action of multiple targeting mechanisms). These vectors must also be large enough to comprise all the requirements for the evasion of the body defenses, while still sufficiently small so as not to create undesired blockages of even the smallest of blood vessels - and thus, by definition, nanotechnological.
引用
收藏
页码:343 / 346
页数:4
相关论文
共 45 条
  • [21] Small-scale systems for in vivo drug delivery
    LaVan, DA
    McGuire, T
    Langer, R
    [J]. NATURE BIOTECHNOLOGY, 2003, 21 (10) : 1184 - 1191
  • [22] A novel antiangiogenesis therapy using an integrin antagonist or anti-FLK-1 antibody coated 90Y-labeled nanoparticles
    Li, LY
    Wartchow, CA
    Danthi, SN
    Shen, ZM
    Dechene, N
    Pease, J
    Choi, HS
    Doede, T
    Chu, P
    Ning, SC
    Lee, DY
    Bednarski, MD
    Knox, SJ
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (04): : 1215 - 1227
  • [23] Brain uptake of thiamine-coated nanoparticles
    Lockman, PR
    Oyewumi, MO
    Koziara, JM
    Roder, KE
    Mumper, RJ
    Allen, DD
    [J]. JOURNAL OF CONTROLLED RELEASE, 2003, 93 (03) : 271 - 282
  • [24] Nanoparticle technology for drug delivery across the blood-brain barrier
    Lockman, PR
    Mumper, RJ
    Khan, MA
    Allen, DD
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2002, 28 (01) : 1 - 13
  • [25] Nanoshell-enabled photonics-based imaging and therapy of cancer
    Loo, C
    Lin, A
    Hirsch, L
    Lee, MH
    Barton, J
    Halas, NJ
    West, J
    Drezek, R
    [J]. TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2004, 3 (01) : 33 - 40
  • [26] Dynamics and fragmentation of thick-shelled microbubbles
    May, DJ
    Allen, JS
    Ferrara, KW
    [J]. IEEE TRANSACTIONS ON ULTRASONICS FERROELECTRICS AND FREQUENCY CONTROL, 2002, 49 (10) : 1400 - 1410
  • [27] Development of the polymer micelle carrier system for doxorubicin
    Nakanishi, T
    Fukushima, S
    Okamoto, K
    Suzuki, M
    Matsumura, Y
    Yokoyama, M
    Okano, T
    Sakurai, Y
    Kataoka, K
    [J]. JOURNAL OF CONTROLLED RELEASE, 2001, 74 (1-3) : 295 - 302
  • [28] Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours
    Neuwelt, EA
    Várallyay, P
    Bagó, AG
    Muldoon, LL
    Nesbit, G
    Nixon, R
    [J]. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2004, 30 (05) : 456 - 471
  • [29] Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles
    O'Neal, DP
    Hirsch, LR
    Halas, NJ
    Payne, JD
    West, JL
    [J]. CANCER LETTERS, 2004, 209 (02) : 171 - 176
  • [30] Engineering tumor-targeted gadolinium hexanedione nanoparticles for potential application in neutron capture therapy
    Oyewumi, MO
    Mumper, RJ
    [J]. BIOCONJUGATE CHEMISTRY, 2002, 13 (06) : 1328 - 1335